Itulazax (Betula Verrucosa (108))

Betula verrucosa provides standardized birch pollen proteins that stimulate regulatory immune pathways when administered sublingually. This promotes a shift from IgE‑mediated responses toward IgG4 production and regulatory T‑cell activity, decreasing mast‑cell activation and clinical allergy symptoms.

The dosing regimen for Itulazax is determined individually by a qualified healthcare professional based on the patient’s sensitivity, age, and treatment goals. The prescriber sets the initial dose and any subsequent titration steps.

Safety data for Itulazax in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their physician before starting therapy.

To order Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Itulazax is a sublingual extract, whereas some alternatives are tablet‑based or injectable extracts. Sublingual delivery offers ease of administration without injections and can be started in an outpatient setting, but efficacy and safety profiles are comparable when prescribed and monitored appropriately.

Itulazax should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain potency.

Itulazax is administered sublingually, typically by placing the prescribed dose under the tongue and holding it for a few minutes before swallowing. The first dose and any dose adjustments should be given under medical supervision with observation for adverse reactions.

The most serious risks include severe systemic allergic reactions such as anaphylaxis, angioedema, and respiratory distress. Patients should be monitored after the initial dose and instructed to seek immediate medical attention if signs of a severe reaction develop.

Itulazax is contraindicated in individuals with a known hypersensitivity to Betula verrucosa extract or any excipients, those with uncontrolled severe asthma, or patients who have experienced a severe systemic reaction to a previous dose of the same extract.